Mounting evidence suggests that immunotherapies are a promising new class of anticancer
therapies. However, the immunosuppressive tumor microenvironment (TME), poor …

Despite their potential, conventional whole-cell cancer vaccines prepared by freeze–
thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent …

Nanomedicine with immunotherapy offers opportunities to target cancer in an effective
manner; however, it remains challenging. We herein report a photothermal material loaded …

Liposomal nanoparticles are a heterogeneous group of engineered drug carriers that have
tremendous therapeutic potential in the treatment of cancer. They increase tumor drug …

Immunotherapy has been successfully used in the treatment of multiple malignancies, but
clinical studies revealed low response rates. Thus, the development of new effective …

Nanotechnologies are rapidly increasing their role in immuno-oncology in line with the need
for novel therapeutic strategies to treat patients unresponsive to chemotherapies and …

Immunogenic chemotherapy is a promising approach in cancer treatment, but the number of
drugs capable of inducing immunogenic cell death is limited, and chronic immunogenic …

Tumor hypoxia is confirmed to be associated with the formation of tumor
immunosuppression, a general feature of solid tumors, and thus attenuates the effectiveness …

The tumor immune microenvironment (TIME) is comprised of a complex milieu that
contributes to stunting antitumor immune responses by restricting T cells to accumulate in …

Immunotherapy has achieved prominent clinical efficacy in combating cancer and has
recently become a mainstream treatment strategy. However, achieving broad efficacy with a …